PUBLIC COMPANY
save$AARDAardvark Therapeutics, Inc.
$AARD6.7400+3.06%San Diego, CA, USupdated 17h ago
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
- phase3The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
- phase2A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
- phase2A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
- phase2Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
- phase2Study to Evaluate ARD-101 in Adults With Obesity
🐶 Hiring Signal
News
- Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin assetPlus, news about Tenaya’s TN-401 and Taiho’s Inqovi. 📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placed a full clinical hold on the company's candidate for ...endpoints · 3mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that